Pregnancy: Tobramycin crosses the placenta. No reports linking the use of tobramycin to congenital defects have been located. Ototoxicity, which is known to occur after tobramycin therapy in humans, has not been reported as an effect of in utero exposure. However, other aminoglycosides (streptomycin) have been associated with infant ototoxicity following in utero exposure. If tobramycin is required to treat a serious maternal infection, benefit likely outweighs potential risk.
Breastfeeding: Only very small amounts of tobramycin are found in breast milk and tobramycin is poorly orally absorbed. Likely compatible. Monitor infant for gastrointestinal side effects.
Maternal use of an ear drop or eye drop that contains tobramycin presents little or no risk for the nursing infant.